Kwong Kwok Wong, Ph.D.
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
About Dr. Kwong K. Wong
Kwong K. Wong, Ph.D. has a broad background in biology and biochemistry, with specialized training in molecular genetics, genomics, DNA sequencing analyses, gene expression profiling, and data mining. He is an inventor or co‑inventor on six issued U.S. patents. Dr. Wong’s laboratory is dedicated to deciphering the molecular pathogenesis of ovarian cancer, with a translational focus on identifying prognostic biomarkers and therapeutic targets to enable individualized therapy. His current research centers on rare gynecologic cancers, particularly low‑grade serous carcinoma (LGSOC) and sarcoma. One of his major projects focuses on elucidating the mechanisms underlying resistance of LGSOC to MEK inhibitors.
Dr. Wong actively collaborates with faculty at The University of Texas MD Anderson Cancer Center and investigators at other institutions. He is a regular member of the graduate faculty at the University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, where he has mentored numerous graduate students and clinical fellows. His commitment to education has been recognized with the Faculty Educator of the Month award.
Current Projects
- Understanding the molecular pathogenesis of low‑grade serous ovarian cancer and developing novel therapeutic strategies.
- Developing genetic mouse models for gynecologic cancers.
- Deciphering the pathogenesis of uterine leiomyosarcoma and carcinosarcoma.
Present Title & Affiliation
Primary Appointment
Professor, Gynecologic Oncology and Reproductive Medicine - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Gynecologic Oncology and Reproductive Medicine - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty Member, University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX
Education & Training
Degree-Granting Education
| 1990 | The Chinese University of Hong Kong, Hong Kong, CN, Ph.D. in Biology (Molecular Biology) |
| 1987 | The Chinese University of Hong Kong, Hong Kong, CN, MPhil in Biology (Bacterial Genetics) |
| 1984 | The Chinese University of Hong Kong, Hong Kong, CN, BS in Biology/Biochemistry (Hons) |
| 2025 | Texas McCombs School of Business, The University of Texas, Austin, Austin, TX, US, Data Science, Post-Graduate Certification in Data Science and Business Analytics |
Postgraduate Training
| 2024-2025 | Post Graduate Program in Data Science and Business Analytics, Data Science, The University of Texas Austin, Austin, TX |
| 1995-1996 | Research Fellowship, Battelle Memorial Institute, Pacific Northwest National Laboratory, Richland, Washington |
| 1990-1995 | Research Fellowship, Genomics, California Institute of Biological Research, La Jolla, California |
Licenses & Certifications
| 2021 | Weatherhead Executive Education: MD Anderson Cancer Center Leadership Institute Emotional Intelligence Certificate |
Experience & Service
Faculty Academic Appointments
Associate Professor, Pediatrics - Research, Baylor College of Medicine, Houston, TX, 2006 - 2010
Associate Professor, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2011
Associate Professor, Gynecologic Oncology and Reproductive Medicine - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2011
Associate Professor, The Chinese University of Hong Kong, Hong Kong, 2004 - 2013
Assistant Professor, Pediatrics, Baylor College of Medicine, Houston, TX, 2001 - 2005
Senior Research Scientist, Molecular Biosciences, Pacific Northwest National Laboratory, Richland, WA, 1996 - 2001
Research Scientist, Molecular Biosciences, Pacific Northwest National Laboratory, Richland, WA, 1996 - 1996
Administrative Appointments/Responsibilities
Faculty Senate Chair-Elect and Chair, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2021
Member of the Executive Council of the Faculty Senate, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2020
Other Professional Positions
Consultant, Janssen Research & Development, LLC, Princeton, New Jersey, 2017 - 2017
Member, American Society of Clinical Oncology, Alexandria, VA, 2014 - Present
Member, Multidiciplinary Gynecological Cancer Translational Research Tissue Bank Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - Present
Cancer Center Member, Baylor College of Medicine, Houston, TX, 2004 - 2010
Director, Microarray Laboratory, Texas Children's Cancer Center, Houston, TX, 2001 - 2006
Member, American Association for Cancer Research, Philadelphia, PA, 1999 - Present
Extramural Institutional Committee Activities
Chair, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - 2021
Member, Rice and MDACC Think Tank Discussion: Exploring shared strategies in research and education, The University of Texas MD Anderson Cancer Center, 2021 - 2021
Member, Charles A LeMaistre Outstanding Achievement Award Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2021
Panelist, Town Hall discuss Racism in science with a special focus on Asian trainees and Asian Americans, The University of Texas MD Anderson Cancer Center, 2021
Member, CFO Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2021
Member, Academic Advisory Council (ACC), The University of Texas MD Anderson Cancer Center, 2020 - 2022
Member, SPMC Research Science & Education Faculty Task Force, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Member, Research Leadership Team (RLT), The University of Texas MD Anderson Cancer Center, 2020 - 2021
Member, President Advisory Council (PAC), The University of Texas MD Anderson Cancer Center, 2020 - 2021
Member, RESEARCH COVID-19 CORE LEADERSHIP TEAM (R-CCLT), The University of Texas MD Anderson Cancer Center, 2020 - 2021
Elected Member, Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Member, Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2011 - 2023
Designated Review Member, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2015
Member, Multidisciplinary Gynecological Cancer Translational Research Tissue Bank Committee, The University of Texas MD Anderson Cancer Center, 2005 - Present
Editorial Activities
Editorial Board member, Cancers, 2023 - Present
Editor-in-Chief, Advances in Modern Oncology Research, 2017 - 2019
Academic Editor, PLOS ONE, 2014 - 2017
Senior Editorial Board Member, American Journal of Clinical and Experimental Obstetrics and Gynecology, 2013 - Present
Member of Editorial Review Board, Recent Patents on Anti-Cancer Drug Discovery, 2010 - Present
Member of Editorial Review Board, International Journal of Clinical and Experimental Pathology, 2010 - Present
Member of Editorial Review Board, Research & Reviews in Biosciences, 2006 - Present
Honors & Awards
| 2016 | Faculty Educator of the Month (August), UT MD Anderson Cancer Center |
| 2010 | Finalist, Julie and Ben Rogers Award for Excellence in the area of Education, UT MD Anderson Cancer Center |
| 2010 | Who's Who in America, Marquis Who's Who |
| 2003 | Children's Oncology Group Young Investigator Award, Children's Oncology Group |
| 2000 | EHSD Outstanding Performance Award, Pacific Northwest National Laboratory |
| 2000 | Director's Award, Pacific Northwest National Laboratory |
| 1998 - 2000 | Certificate of Appreciation, Office of Research, Department of Energy |
| 1988 - 1990 | Sir Edward Yude Memorial Scholarship |
| 1984 | LNP Award for Balanced Education, The Chinese University of Hong Kong |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2019. Molecular characteristics of rare epithelial ovarian tumors and therapeutic implication. Invited. Stephenson Cancer Center, Oklahoma University Health Science Center. Oklahoma City, OK, US.
- 2019. Molecular Changes in low-grade serous carcinoma and their translational potential. Invited. Division of Gynecologic Oncology, University of Miami. Miami, FL, US.
International Presentations
- 2026. BIOMARKERS OF RESPONSE TO RIBOCICLIB PLUS LETROZOLE IN RECURRENT LOW-GRADE SEROUS OVARIAN CARCINOMA: A GOG-3026 CORRELATIVE STUDY. Panelist. The IGCS 2026 Annual Global Meeting.
- 2023. Deciphering the adaptive trametinib resistance in low-grade ovarian serous carcinoma and its translational potential. Invited. Joint Meeting of the International Ovarian Cancer Research Consortium and The International Society of Precision Cancer Medicine. Oklahoma City, US.
- 2017. The challenge of targeted therapies in epithelial ovarian cancer. Invited. 2nd International Congress on Contemporary Issues in Women Cancers & Gynecologic Oncology, US.
Formal Peers
- 2019. Uterine Fibroid Mouse Model. Invited. Rockville, MD, US.
- 2017. Cancer Biology. Invited. Hong Kong, CN.
- 2017. Targeted Therapy for epithelial ovarian cancer. Invited. Hong Kong, CN.
- 2016. Molecular Genetics of Ovarian Cancer. Invited. Hong Kong, Hong Kong, CN.
- 2016. Molecular Perspectives of Rare Epithelial Ovarian Tumors and Therapeutic Implication. Invited. Hong Kong, HK.
- 2015. Molecular Pathogenesis and targeted therapy for low-grade ovarian serous carcinomas. Invited. Shanghai, CN.
- 2014. Molecular Pathogenesis and targeted therapy for low-grade ovarian serous carcinomas. Invited. Kaohsiung, Kaohsiung, TW.
- 2012. Secretory Proteins from cancer associated fibroblast as potential therapeutic targets. Invited. Oklahoma City, OK, US.
- 2010. Molecular Pathogenesis of Low-grade serous ovarian cancer. Invited. Hong Kong, CN.
- 2007. Progress in genome science and medicine. Invited. Houston, TX, US.
- 2007. Pathogenesis of Ovarian Cancer. Invited. San Diego, CA, US.
- 2006. Progress in Genome Science. Invited. Hong Kong, CN.
- 2005. Genomics technologies for cancer research. Invited. Hong Kong, CN.
Selected Publications
Peer-Reviewed Articles
- Au Yeung, CL, Tsuruga, T, Talor, MA, Pacheco, YJ, He, G, Siddik, ZH, Cha, BJ, Kwan, SY, Wong, KK, Yip, KP, Mok, S. MicroRNA-625-3p Increases Chemosensitivity in Ovarian Cancer Cells Through Decreasing SSX2IP-Mediated Cisplatin Export in Extracellular Vesicles. Cancers 18(5), 2026. e-Pub 2026. PMID: 41827805.
- Hollis, RL, Miller, A, Lankes, HA, Wong, KK, Rodgers, WH, Millan, D, Carty, K, Coleman, R, Moore, KM, Secord, AA, O’Malley, DM, Chan, J, Hagemann, AR, Gaillard, S, Guntupalli, SR, Edelson, M, Rose, PG, Dorigo, O, Banerjee, S, Ewing, A, Churchman, M, Sood, AK, Herrington, CS, Gourley, C, Gershenson, DM. Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS. Clinical Cancer Research 32(4):724-734, 2026. e-Pub 2026. PMID: 41378992.
- Tarney CM, Mhawech-Fauceglia P, Ogata JD, Oliver J, Abulez T, Branton PA, Movahedi-Lankarani S, Hood BL, Conrads KA, Rosalik K, Wong K, Gershenson DM, Lee S, Sood AK, Bast Jr RC, Darcy KM, Phippen NT, Maxwell G, Conrads TP, Bateman NW. Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers. Clinical Proteomics 22(33), 2025. e-Pub 2025. PMID: 41053579.
- Li, J, Welte, T, Calzoncinth, K, Vuttaradhi, VK, Brodsky, AL, Wong, KK, Sebastian, MM, Lawson, BC, Kingsley, CV, Hillman, RT. An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor. Gynecologic oncology 194:125-130, 2025. e-Pub 2025. PMID: 40221170.
- Ng, CW, Wong, KK, Lawson, BC, Ferri-Borgogno, S, Mok, S. Spatial transcriptome reveals histology-correlated immune signature learnt by deep learning attention mechanism on H&E-stained images for ovarian cancer prognosis. Journal of translational medicine 23(1), 2025. e-Pub 2025. PMID: 39856778.
- Ng, CW, Tsang, YT, Gershenson, DM, Wong, KK. The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers. British journal of cancer 130(11):1875-1884, 2024. e-Pub 2024. PMID: 38582811.
- Treekitkarnmongkol W, Solis LM, Sankaran D, Gagea M, Singh PK, Mistry R, Nguyen T, Kai K, Liu J, Sasai K, Jitsumori Y, Liu J, Nagao N, Stossi F, Mancini MA, Wistuba II, Thompson AM, Lee JM, Cadiñanos J, Wong K, Abbott CM, Sahin AA, Liu S, Katayama H, Sen S. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Science Signaling 17(826):17, 2024. e-Pub 2024. PMID: 38442201.
- Ng, CW, Wong, KK. Deep learning-enabled breast cancer endocrine response determination from H&E staining based on ESR1 signaling activity. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 38052873.
- Grisham, RN, Slomovitz, BM, Andrews, N, Banerjee, S, Brown, J, Carey, M, Chui, H, Coleman, R, Fader, AN, Gaillard, S, Gourley, C, Sood, AK, Monk, BJ, Moore, K, Ray-Coquard, I, Shih, IM, Westin, SN, Wong, KK, Gershenson, DM. Low-grade serous ovarian cancer. International Journal of Gynecological Cancer 33(9):1331-1344, 2023. e-Pub 2023. PMID: 37591609.
- Ferri-Borgogno, S, Zhu, Y, Sheng, J, Burks, JK, Gomez, JA, Wong, KK, Wong, ST, Mok, S. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors. Cancer Research 83(9):1503-1516, 2023. e-Pub 2023. PMID: 36787106.
- Ng, CW, Wong, KK. Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry. Journal of Ovarian Research 15(1), 2022. e-Pub 2022. PMID: 35610648.
- Wong, KK, Bateman, NW, Ng, CW, Tsang, YT, Sun, CC, Celestino, J, Nguyen, T, Malpica, A, Hillman, RT, Zhang, J, Futreal, A, Rojas, C, Conrads, KA, Hood, BL, Dalgard, C, Wilkerson, MD, Phippen, NT, Conrads, TP, Maxwell, GL, Sood, AK, Gershenson, DM. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. Journal of translational medicine 20(1), 2022. e-Pub 2022. PMID: 36528667.
- Fu, C, Wang, J, Pallikkuth, S, Ding, Y, Chen, J, Wren, JD, Yang, Y, Wong, KK, Kameyama, H, Jayaraman, M, Munshi, A, Tanaka, T, Lidke, KA, Zhang, XA. EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation. Cellular and Molecular Life Sciences 79(7), 2022. e-Pub 2022. PMID: 35773608.
- Gershenson, DM, Sun, CC, Westin, SN, Eyada, M, Cobb, LP, Nathan, LC, Sood, AK, Malpica, A, Hillman, RT, Wong, KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecologic oncology 165(3):560-567, 2022. e-Pub 2022. PMID: 35606067.
- Choi, PW, Bahrampour, A, Ng, SK, Liu, SK, Qiu, W, Xie, F, Kuo, WP, Kwong, J, Hales, KH, Hales, DB, Wong, KK, Norwitz, ER, Chow, CK, Berkowitz, RS, Ng, SW. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer. Scientific reports 10(1), 2020. e-Pub 2020. PMID: 33208870.
- Kun, EH, Tsang, YT, Lin, S, Pan, S, Medapalli, T, Malpica, A, Richards, JS, Gershenson, DM, Wong, KK. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS G12D or KRAS G12V mutations. Scientific reports 10(1), 2020. e-Pub 2020. PMID: 33244099.
- Izaguirre, DI, Ng, CW, Kwan, SY, Kun, EH, Tsang, YT, Gershenson, DM, Wong, KK. The role of GDF15 in regulating the canonical pathways of the tumor microenvironment in wild-type P53 ovarian tumor and its response to chemotherapy. Cancers 12(10):1-18, 2020. e-Pub 2020. PMID: 33086658.
- Cobb, LP, Sun, CC, Iyer, RB, Nick, AM, Fleming, N, Westin, SN, Sood, AK, Wong, KK, Silva, EG, Gershenson, DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum. Gynecologic oncology 158(3):653-658, 2020. e-Pub 2020. PMID: 32709538.
- Zhang, L, Kwan, SY, Wong, KK, Solaman, PT, Lu, KH, Mok, S. Pathogenesis and clinical management of uterine serous carcinoma. Cancers 12(3), 2020. e-Pub 2020. PMID: 32183290.
- Kwan, SY, Au Yeung, CL, Yeung, T, Rynne-Vidal, A, Wong, KK, Risinger, JI, Lin, H, Schmandt, R, Yates, MS, Mok, S, Lu, KH. Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) promotes uterine serous cancer cell proliferation and cell cycle progression. Cancers 12(1), 2020. e-Pub 2020. PMID: 31906456.
- Hisamatsu, T, McGuire, MH, Wu, S, Rupaimoole, R, Pradeep, S, Bayraktar, E, Noh, K, Hu, W, Hansen, JM, Lyons, YA, Gharpure, K, Nagaraja, AS, Mangala, LS, Mitamura, T, Rodriguez-Aguayo, C, Eun, YG, Rose, J, Bartholomeusz, G, Ivan, C, Lee, J, Matsuo, K, Frumovitz, M, Wong, KK, Lopez Berestein, G, Sood, AK. PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer. Molecular cancer therapeutics 18(1):162-172, 2019. e-Pub 2019. PMID: 30305341.
- Padmanabhan, A, Candelaria, NR, Wong, KK, Nikolai, BC, Lonard, DM, O'Malley, B, Richards, JS. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nature communications 9(1), 2018. e-Pub 2018. PMID: 29593334.
- Yeung, T, Tsai, CC, Leung, SC, Au Yeung, CL, Thompson, MS, Lu, KH, Freedman, RS, Birrer, MJ, Wong, KK, Mok, S. ISG15 promotes ERK1 ISGylation, CD8+ T cell activation and suppresses ovarian cancer progression. Cancers 10(12), 2018. e-Pub 2018. PMID: 30469497.
- Leung, SC, Yeung, T, Yip, KP, Wong, KK, Ho, SY, Mangala, LS, Sood, AK, Lopez Berestein, G, Sheng, J, Wong, ST, Birrer, MJ, Mok, S. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. Journal of Clinical Investigation 128(2):589-606, 2018. e-Pub 2018. PMID: 29251630.
- Matsuo, K, Wong, KK, Fotopoulou, C, Blake, EA, Robertson, SE, Pejovic, T, Frimer, M, Pardeshi, V, Hu, W, Choi, JS, Sun, CC, Richmond, AM, Marcus, JZ, Hilliard, MA, Mostofizadeh, S, Mhawech-Fauceglia, P, Abdulfatah, E, Post, MD, Saglam, O, Shahzad, MM, Karabakhtsian, RG, Ali-Fehmi, R, Gabra, H, Roman, LD, Sood, AK, Gershenson, DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. Journal of Surgical Oncology 117(2):236-244, 2018. e-Pub 2018. PMID: 28787528.
- Wang, J, Jia, N, Lyv, T, Wang, C, Tao, X, Wong, KK, Li, Q, Feng, W. Paired box 2 promotes progression of endometrial cancer via regulating cell cycle pathway. Journal of Cancer 9(20):3743-3754, 2018. e-Pub 2018. PMID: 30405846.
- Yeung, T, Leung, SC, Wong, KK, Gutierrez-Hartmann, A, Kwong, J, Gershenson, DM, Mok, S. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget 8(10):16951-16963, 2017. e-Pub 2017. PMID: 28199976.
- Ren, YA, Mullany, LK, Liu, Z, Herron, A, Wong, KK, Richards, JS. Mutant p53 promotes epithelial ovarian cancer by regulating tumor differentiation, metastasis, and responsiveness to steroid hormones. Cancer Research 76(8):2206-2218, 2016. e-Pub 2016. PMID: 26964623.
- Malpica, A, Wong, KK. The molecular pathology of ovarian serous borderline tumors. Annals of Oncology 27:i16-i19, 2016. e-Pub 2016. PMID: 27141064.
- Au Yeung, CL, Co, NN, Tsuruga, T, Yeung, T, Kwan, SY, Leung, SC, Li, Y, Lu, ES, Kwan, K, Wong, KK, Schmandt, R, Lu, KH, Mok, S. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nature communications 7, 2016. e-Pub 2016. PMID: 27021436.
- Lin, CC, Tsai, CC, Lee, JM, Fang, CH, Chang, KS, Wong, KK, Lin, CT, Qiu, JT. The efficacy of a novel vaccine approach using tumor cells that ectopically express a codon-optimized murine GM-CSF in a murine tumor model. Vaccine 34(1):134-141, 2016. e-Pub 2016. PMID: 26546261.
- Kwan, SY, Cheng, X, Tsang, YT, Choi, JS, Kwan, SY, Izaguirre, DI, Kwan, HS, Gershenson, DM, Wong, KK. Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells. Oncotarget 7(35):56933-56943, 2016. e-Pub 2016. PMID: 27486766.
- Jia, N, Wang, J, Li, Q, Tao, X, Chang, K, Hua, K, Yu, Y, Wong, KK, Feng, W. DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer. Oncotarget 7(51):84785-84797, 2016. e-Pub 2016. PMID: 27764784.
- Gershenson, DM, Sun, CC, Wong, KK. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. British journal of cancer 113(9):1254-1258, 2015. e-Pub 2015. PMID: 26484411.
- Gershenson, DM, Bodurka, DC, Lu, KH, Nathan, LC, Milojevic, L, Wong, KK, Malpica, A, Sun, CC. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum. Journal of Clinical Oncology 33(24):2675-2682, 2015. e-Pub 2015. PMID: 26195696.
- Crane, EK, Kwan, SY, Izaguirre, DI, Tsang, YT, Mullany, LK, Zu, Z, Richards, JS, Gershenson, DM, Wong, KK. Nutlin-3a. PloS one 10(8), 2015. e-Pub 2015. PMID: 26248031.
- Mullany, LK, Wong, KK, Marciano, DC, Katsonis, P, King-Crane, ER, Ren, YA, Lichtarge, O, Richards, JS. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. Neoplasia (United States) 17(10):789-803, 2015. e-Pub 2015. PMID: 26585234.
- Qiu, MT, Fan, Q, Zhu, Z, Kwan, SY, Chen, L, Chen, JH, Ying, ZL, Zhou, Y, Gu, W, Wang, LH, Cheng, WW, Zeng, J, Wan, X, Mok, S, Wong, KK, Bao, W. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget 6(31):31702-31720, 2015. e-Pub 2015. PMID: 26397136.
- Tone, AA, McConechy, MK, Yang, W, Ding, J, Yip, S, Kong, E, Wong, KK, Gershenson, DM, Mackay, H, Shah, S, Gilks, CB, Tinker, AV, Clarke, BA, McAlpine, JN, Huntsman, DG. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC cancer 14(1), 2014. e-Pub 2014. PMID: 25523272.
- Mullany, LK, Liu, Z, Wong, KK, Deneke, V, Ren, YA, Herron, A, Richards, JS. Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Molecular Endocrinology 28(1):127-137, 2014. e-Pub 2014. PMID: 24264574.
- Leung, SC, Yeung, T, Yip, KP, Pradeep, S, Balasubramanian, L, Liu, J, Wong, KK, Mangala, LS, Armaiz Pena, GN, Lopez Berestein, G, Sood, AK, Birrer, MJ, Mok, S. Calcium dependent FAK/CREB/TNNC1 signaling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature communications 5, 2014. e-Pub 2014. PMID: 25277212.
- Tsang, YT, Deavers, MT, Sun, CC, Kwan, SY, Kuo, E, Malpica, A, Mok, S, Gershenson, DM, Wong, KK. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. Journal of Pathology 231(4):449-456, 2013. e-Pub 2013. PMID: 24549645.
- Wong, KK, Izaguirre, DI, Kwan, SY, King, ER, Deavers, MT, Sood, AK, Mok, S, Gershenson, DM. Poor survival with wild-type TP53 ovarian cancer?. Gynecologic oncology 130(3):565-569, 2013. e-Pub 2013. PMID: 23800698.
- Yeung, T, Leung, SC, Wong, KK, Samimi, G, Thompson, MS, Liu, J, Zaid, TM, Ghosh, S, Birrer, MJ, Mok, S. TGF-β Modulates ovarian cancer invasion by upregulating CAF-Derived versican in the tumor microenvironment. Cancer Research 73(16):5016-5028, 2013. e-Pub 2013. PMID: 23824740.
- Yang, G, Mercado-Uribe, I, Multani, AS, Sen, S, Shih, IM, Wong, KK, Gershenson, DM, Liu, J. RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. International journal of cancer 133(2):275-285, 2013. e-Pub 2013. PMID: 23319376.
- Song, H, Kwan, SY, Izaguirre, DI, Zu, Z, Tsang, YT, Tung, CS, King, ER, Mok, S, Gershenson, DM, Wong, KK. PAX2 expression in ovarian cancer. International journal of molecular sciences 14(3):6090-6105, 2013. e-Pub 2013. PMID: 23502471.
- Zaid, TM, Yeung, T, Thompson, MS, Leung, SC, Harding, T, Co, NN, Schmandt, R, Kwan, SY, Rodriguez-Aguay, C, Lopez Berestein, G, Sood, AK, Wong, KK, Birrer, MJ, Mok, S. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research 19(4):809-820, 2013. e-Pub 2013. PMID: 23344261.
- Mullany, LK, Liu, Z, King, ER, Wong, KK, Richards, JS. Wild-type Tumor Repressor Protein 53 (TRP53) promotes ovarian cancer cell survival. Endocrinology 153(4):1638-1648, 2012. e-Pub 2012. PMID: 22396451.
- King, ER, Zu, Z, Tsang, YT, Deavers, MT, Malpica, A, Mok, S, Gershenson, DM, Wong, KK. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecologic oncology 123(1):13-18, 2011. e-Pub 2011. PMID: 21726895.
- Matsuo, K, Nishimura, M, Bottsford-Miller, J, Huang, J, Komurov, K, Armaiz Pena, GN, Shahzad, MM, Stone, RL, Roh, JW, Sanguino, A, Lu, C, Im, DD, Rosenshien, NB, Sakakibara, A, Nagano, T, Yamasaki, M, Enomoto, T, Kimura, T, Ram, P, Schmeler, KM, Gallick, GE, Wong, KK, Frumovitz, M, Sood, AK. Targeting Src in mucinous ovarian carcinoma. Clinical Cancer Research 17(16):5367-5378, 2011. e-Pub 2011. PMID: 21737505.
- Mullany, LK, Fan, HY, Liu, Z, White, LD, Marshall, A, Gunaratne, PH, Anderson, ML, Creighton, CJ, Xin, L, Deavers, MT, Wong, KK, Richards, JS. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30(32):3522-3536, 2011. e-Pub 2011. PMID: 21423204.
- King, ER, Tung, CS, Tsang, YT, Zu, Z, Lok, GT, Deavers, MT, Malpica, A, Wolf, JK, Lu, KH, Birrer, MJ, Mok, S, Gershenson, DM, Wong, KK. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. American Journal of Surgical Pathology 35(6):904-912, 2011. e-Pub 2011. PMID: 21451362.
- Wong, KK, Tsang, YT, Deavers, MT, Mok, S, Zu, Z, Sun, CC, Malpica, A, Wolf, JK, Lu, KH, Gershenson, DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. American Journal of Pathology 177(4):1611-1617, 2010. e-Pub 2010. PMID: 20802181.
- Mine, T, Matsueda, S, Gao, H, Li, Y, Wong, KK, Peoples, GE, Ferrone, S, Ioannides, CG. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44Hi progenitors of taxol-resistant ovarian cancer cells. Oncology reports 23(6):1537-1543, 2010. e-Pub 2010. PMID: 20428807.
- Mok, S, Bonome, T, Vathipadiekal, V, Bell, A, Johnson, ME, Wong, KK, Park, DC, Hao, K, Yip, KP, Donninger, H, Ozbun, L, Samimi, G, Brady, JN, Randonovich, M, Pise-Masison, CA, Barrett, JC, Wong, WH, Welch, WR, Berkowitz, RS, Birrer, MJ. A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor. Cancer cell 16(6):521-532, 2009. e-Pub 2009. PMID: 19962670.
- Tung, CS, Mok, S, Tsang, YT, Zu, Z, Song, H, Liu, J, Deavers, MT, Malpica, A, Wolf, JK, Lu, KH, Gershenson, DM, Wong, KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Modern Pathology 22(9):1243-1250, 2009. e-Pub 2009. PMID: 19525924.
- Mine, T, Matsueda, S, Li, Y, Tokumitsu, H, Gao, H, Danes, C, Wong, KK, Wang, X, Ferrone, S, Ioannides, CG. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunology, Immunotherapy 58(8):1185-1194, 2009. e-Pub 2009. PMID: 19048252.
- Adesina, AM, Lopez-Terrada, D, Wong, KK, Gunaratne, PH, Nguyen, Y, Pulliam, J, Margolin, J, Finegold, MJ. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Human Pathology 40(6):843-853, 2009. e-Pub 2009. PMID: 19200578.
- Kwong, J, Franky, LC, Wong, KK, Birrer, MJ, Archibald, KM, Balkwill, F, Berkowitz, RS, Mok, S. Inflammatory cytokine tumor necrosis factor α confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11(6):529-541, 2009. e-Pub 2009. PMID: 19484142.
- Lin, YG, Immaneni, A, Merritt, WM, Mangala, LS, Kim, MS, Shahzad, MM, Tsang, YT, Armaiz Pena, GN, Lu, C, Kamat, AA, Han, LY, Spannuth, WA, Nick, AM, Landen, CN, Wong, KK, Gray, MJ, Coleman, R, Bodurka, DC, Brinkley, WR, Sood, AK. Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth. Clinical Cancer Research 14(17):5437-5446, 2008. e-Pub 2008. PMID: 18765535.
- Park, DC, Geun Yeo, S, Wilson, MR, Yerbury, JJ, Kwong, J, Welch, WR, Choi, YK, Birrer, MJ, Mok, S, Wong, KK. Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-972, 2008. e-Pub 2008. PMID: 18714397.
- Shu, Q, Wong, KK, Su, JM, Adesina, AM, Li, TY, Tsang, YT, Antalffy, BA, Baxter, PA, Perlaky, L, Yang, J, Dauser, R, Chintagumpala, M, Blaney, SM, Lau, CC, Li, XN. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells 26(6):1414-1424, 2008. e-Pub 2008. PMID: 18403755.
- Takei, H, Yogeswaren, ST, Wong, KK, Mehta, V, Chintagumpala, M, Dauser, R, Lau, CC, Adesina, AM. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. Journal of neuro-oncology 86(2):183-190, 2008. e-Pub 2008. PMID: 17690840.
- Wong, KK, Lu, KH, Malpica, A, Bodurka, DC, Shvartsman, HS, Schmandt, R, Thornton, A, Deavers, MT, Silva, EG, Gershenson, DM. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. International Journal of Gynecological Pathology 26(4):404-409, 2007. e-Pub 2007. PMID: 17885490.
- Birrer, MJ, Johnson, ME, Hao, K, Wong, KK, Park, DC, Bell, A, Welch, WR, Berkowitz, RS, Mok, S. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. Journal of Clinical Oncology 25(16):2281-2287, 2007. e-Pub 2007. PMID: 17538174.
- Li, XN, Shu, Q, Su, JM, Adesina, AM, Wong, KK, Perlaky, L, Antalffy, BA, Blaney, SM, Lau, CC. Differential expression of survivin splice isoforms in medulloblastomas. Neuropathology and Applied Neurobiology 33(1):67-76, 2007. e-Pub 2007. PMID: 17239009.
- Wong, KK, Tsang, YT, Chang, YM, Su, JM, Di Francesco, AM, Meco, D, Riccardi, R, Perlaky, L, Dauser, R, Adesina, AM, Bhattacharjee, M, Chintagumpala, M, Lau, CC. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Research 66(23):11172-11178, 2006. e-Pub 2006. PMID: 17145861.
- Li, Y, Wong, KK, Matsueda, S, Efferson, CL, Chang, DZ, Ioannides, CG, Tsuda, N. Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysis. International journal of molecular medicine 18(6):1127-1139, 2006. e-Pub 2006. PMID: 17089018.
- Kwong, J, Lee, JY, Wong, KK, Zhou, X, Wong, DT, Lo, KW, Welch, WR, Berkowitz, RS, Mok, S. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-278, 2006. e-Pub 2006. PMID: 16756719.
- Feltmate, CM, Lee, KR, Johnson, MD, Schorge, JO, Wong, KK, Hao, K, Welch, WR, Bell, DA, Berkowitz, RS, Mok, S. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clinical Cancer Research 11(21):7651-7657, 2005. e-Pub 2005. PMID: 16278384.
- Tsuda, H, Ito, YM, Ohashi, Y, Wong, KK, Hashiguchi, Y, Welch, WR, Berkowitz, RS, Birrer, MJ, Mok, S. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clinical Cancer Research 11(19 I):6880-6888, 2005. e-Pub 2005. PMID: 16203778.
- Man, TK, Chintagumpala, M, Visvanathan, J, Shen, J, Perlaky, L, Hicks, MJ, Johnson, ME, Davino, NA, Murray, JC, Helman, LJ, Meyer, W, Triche, T, Wong, KK, Lau, CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Research 65(18):8142-8150, 2005. e-Pub 2005. PMID: 16166288.
Review Articles
- Corvigno, S, Johnson, AM, Wong, KK, Cho, MS, Afshar-Kharghan, V, Menter, DG, Sood, AK. Novel Markers for Liquid Biopsies in Cancer Management. Molecular cancer therapeutics 21(7):1067-1075, 2022. e-Pub 2022. PMID: 35545008.
- Kun, EH, Tsang, YT, Ng, CW, Gershenson, DM, Wong, KK. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treatment Reviews 92, 2021. e-Pub 2021. PMID: 33340965.
- Slomovitz, BM, Gourley, C, Carey, M, Malpica, A, Shih, IM, Huntsman, DG, Fader, AN, Grisham, RN, Schlumbrecht, MP, Sun, CC, Ludemann, J, Cooney, GA, Coleman, R, Sood, AK, Mahdi, H, Wong, KK, Covens, A, O'Malley, DM, Lecuru, F, Cobb, LP, Caputo, TA, May, T, Huang, M, Siemon, J, Fernández, ML, Ray-Coquard, I, Gershenson, DM. Low-grade serous ovarian cancer. Gynecologic oncology 156(3):715-725, 2020. e-Pub 2020. PMID: 31969252.
- Noguera, IR, Sun, CC, Wong, KK, Bast Jr, RC, Gershenson, DM. Low-grade serous carcinoma. Gynecologic oncology 130(3):660-666, 2013. e-Pub 2013. PMID: 23707670.
- King, ER, Wong, KK. Insulin-like growth factor. Recent Patents on Anti-Cancer Drug Discovery 7(1):14-30, 2012. e-Pub 2012. PMID: 21875414.
- Wong, KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Patents on Anti-Cancer Drug Discovery 4(1):28-35, 2009. e-Pub 2009. PMID: 19149686.
- Wong, KK. Oral-specific chemical carcinogenesis in mice. Cancer Prevention Research 2(1):10-13, 2009. e-Pub 2009. PMID: 19139012.
- Tung, CS, Wong, KK, Mok, S. Biomarker discovery in ovarian cancer. Women's Health 4(1):27-40, 2008. e-Pub 2008. PMID: 19072449.
- Mok, S, Kwong, J, Welch, WR, Samimi, G, Ozbun, L, Bonome, T, Birrer, MJ, Berkowitz, RS, Wong, KK. Etiology and pathogenesis of epithelial ovarian cancer. Disease markers 23(5-6):367-376, 2007. e-Pub 2007. PMID: 18057520.
- Wong, KK, Gershenson, DM. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Disease markers 23(5-6):377-387, 2007. e-Pub 2007. PMID: 18057521.
- Mok, S, Elias, KM, Wong, KK, Ho, K, Bonome, T, Birrer, MJ. Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches. Advances in Cancer Research 96:1-22, 2006. e-Pub 2006. PMID: 17161674.
Other Articles
- Matsuo, K, Nishimura, M, Bottsford-Miller, J, Huang, J, Komurov, K, Armaiz Pena, GN, Shahzad, MM, Stone, RL, Roh, JW, Sanguino, A, Lu, C, Im, DD, Rosenshien, NB, Sakakibara, A, Nagano, T, Yamasaki, M, Enomoto, T, Kimura, T, Ram, P, Schmeler, KM, Gallick, GE, Wong, KK, Frumovitz, M, Sood, AK Erratum. Clinical Cancer Research 27(15):4450, 2021. PMID: 34341055.
Abstracts
- Bildik G, Ozyurt R, Mao W, Llaurado-Fernandez M, Kim H, Wever OD, Wong KK, Carey MS, Bast RC, Lu Z. Targeting PARP to enhance sensitivity to MEK inhibitors in low-grade serous ovarian cancer. 2025 AACR Annual Meeting.
- Wong K, Ng CW, Tsang Y, Gershenson DM. High throughput drug screening to decipher the mechanisms of trametinib adaptive resistance in low-grade serous ovarian cancer cell lines. AACR Special Conference: Ovarian Cancer October 2023.
- Tsang YT, Oscar Ng CW, Gershenson D, wong K. Estrogen signaling in low-grade serous ovarian carcinoma. American Association for Cancer Research Annual Meeting 2024.
- Ng CW, Wong KK, Lawson B, Ferri-Borgogno S, Mok SC. Convolutional neural network algorithms and hematoxylin-and-eosin-stained images predict clinical outcomes in high-grade serous ovarian cancer patients with advanced age and stage. 2024 AACR Annual Meeting.
- Wong K, Tsang Y, Gershenson DM. Analysis of low-grade serous ovarian cancer by long-read full length transcripts sequencing. American Association for Cancer Research Annual Meeting 2025.
Book Chapters
- Mok, S, Wong, KK, Lu, KH, Munger, K, Nagymanyoki, Z. Molecular basis of gynecologic diseases, 409-424, 2020.
- Mok, S, Wong, KK, Lu, KH, Munger, K, Nagymanyoki, Z. Molecular basis of gynecologic diseases, 507-529, 2018.
- Tung, CS, Wong, KK. Molecular signatures in ovarian cancer, 423-446, 2011.
- Mok, S, Wong, KK, Lu, KH, Munger, K, Nagymanyoki, Z. Molecular Basis of Gynecologic Diseases, 309-322, 2010.
- Mok, S, Wong, KK, Lu, KH, Munger, K, Nagymanyoki, Z. Molecular Basis of Gynecologic Diseases, 465-487, 2009.
Patient Reviews
CV information above last modified August 26, 2026